These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 11590534)
1. Efficacy of nevirapine-based HAART in HIV-1-infected, treatment-naive persons with high and low baseline viral loads. Raffi F; Reliquet V; Podzamczer D; Pollard RB HIV Clin Trials; 2001; 2(4):317-22. PubMed ID: 11590534 [TBL] [Abstract][Full Text] [Related]
2. Nevirapine or efavirenz combined with two nucleoside reverse transcriptase inhibitors compared to HAART: a meta-analysis of randomized clinical trials. Torre D; Tambini R; Speranza F HIV Clin Trials; 2001; 2(2):113-21. PubMed ID: 11590519 [TBL] [Abstract][Full Text] [Related]
3. A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load. Arranz Caso JA; López JC; Santos I; Estrada V; Castilla V; Sanz J; Sanz J; Molina JP; Fernández Guerrero M; Górgolas M HIV Med; 2005 Sep; 6(5):353-9. PubMed ID: 16156884 [TBL] [Abstract][Full Text] [Related]
4. Modest decreases in NNRTI susceptibility do not influence virological outcome in patients receiving initial NNRTI-containing triple therapy. Harrigan PR; Hertogs K; Verbiest W; Larder B; Yip B; Brumme ZL; Alexander C; Tilley J; O'Shaughnessy MV; Montaner JS Antivir Ther; 2003 Oct; 8(5):395-402. PubMed ID: 14640386 [TBL] [Abstract][Full Text] [Related]
5. Nevirapine plus efavirenz plus didanosine: a simple, safe, and effective once-daily regimen for patients with HIV infection. Jordan WC; Jefferson R; Yemofio F; Tolbert L; Conlon V; Carroll H; Green DC; Green A; Green R J Natl Med Assoc; 2003 Dec; 95(12):1152-7. PubMed ID: 14717471 [TBL] [Abstract][Full Text] [Related]
6. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy. Van Vaerenbergh K Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503 [TBL] [Abstract][Full Text] [Related]
7. Triple nucleoside reverse transcriptase inhibitor- vs. nonnucleoside reverse transcriptase inhibitor-containing regimens as first-line therapy: efficacy and durability in a prospective cohort of French HIV-infected patients. Cuzin L; Pugliese P; Bugnon F; Delpierre C; Cua E; Billaud E; Massip P; Raffi F; Dellamonica P HIV Med; 2005 Nov; 6(6):388-95. PubMed ID: 16268820 [TBL] [Abstract][Full Text] [Related]
8. Response to nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-infected children with perinatal exposure to single-dose nevirapine. Musiime V; Ssali F; Kayiwa J; Namala W; Kizito H; Kityo C; Mugyenyi P AIDS Res Hum Retroviruses; 2009 Oct; 25(10):989-96. PubMed ID: 19778270 [TBL] [Abstract][Full Text] [Related]
9. Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study. Matthews GV; Sabin CA; Mandalia S; Lampe F; Phillips AN; Nelson MR; Bower M; Johnson MA; Gazzard BG AIDS; 2002 Jan; 16(1):53-61. PubMed ID: 11741163 [TBL] [Abstract][Full Text] [Related]
10. Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults. Nachega JB; Hislop M; Dowdy DW; Gallant JE; Chaisson RE; Regensberg L; Maartens G AIDS; 2008 Oct; 22(16):2117-25. PubMed ID: 18832875 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of residual viremia and quantitation of soluble CD14 in a large cohort of HIV-infected adults on a long-term non-nucleoside reverse transcriptase inhibitor-based regimen. Allavena C; Rodallec A; Sécher S; Reliquet V; Baffoin S; André-Garnier E; Billaud E; Raffi F; Ferré V J Med Virol; 2013 Nov; 85(11):1878-82. PubMed ID: 23861166 [TBL] [Abstract][Full Text] [Related]